Favrille 3Q Loss Widens on Costs
14th Nov 2006, 20:00 GMT
Biopharmaceutical company Favrille said its Q3 loss widened as costs rose with preparations to market cancer treatment Favid.
Favrille 3Q Loss Widens on Costs related news:
- Novavax 3Q Loss Widens on Research Costs — Operations-Related News from StratCenter.com
- Iomai 3Q Loss Widens — StratWire - Business of Healthcare NewsFeed
- Repros Therapeutics 3Q Loss Widens — Financial News News from StratCenter.com
- GMH 3Q loss widens, no guidance offered — bizjournals.com Banking & Financial Services:Investing headlines
- UGS Corp. posts wider 3Q loss — Latest news from Dallas Business Journal
- PFSweb loss widens — bizjournals.com High Tech:E-Commerce headlines
- US LEC loss widens in third quarter — Latest news from Charlotte Business Journal
- Favrille Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial Of FavId Following Rituxan — Health News from Medical News Today
- Revenues decline, loss widens for Spheris Inc. — Latest news from Nashville Business Journal
- PokerTek posts 3Q loss of $2.3M — Latest news from Charlotte Business Journal
Latest news from StratWire - Business of Healthcare NewsFeed:
- Alliance Names New COO
- NHCAA to Award Those Who Fight and Expose the Deadly Side of Health Care Fraud
- More Than 2 mln Cancer Patients Treated with BrainLAB m3 Shaped Beam Radiosurgery
- PA's Continuing Trend Towards Total Body Reconstruction Keeps Consumers Demanding Comprehensive Direct-To-Consumer-Education (DTCE )
- Dr Farzad Yaghouti of Global Laser Vision San Diego Wins 'Best Lasik Surgeon 2006'
- 1st Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Medical Mutual of OH Financial Investigator Wins Top Nat'l Fraud-Fighting Award
- Intelligent Medical Objects and Bond Technologies Sign Multi-year Agreement
- M-CARE's Medicaid Plan Recognized as One of the Top Health Plans by US News & World Report/NCQA
- Fitch: MCH rates 'A-' on bonds